July’s top five retina articles
Click Here to Manage Email Alerts
July’s most-read retina articles include a number of meeting items, including long-term study results of Iluvien in DME and an examination of intravitreal ranibizumab with delayed laser photocoagulation in ROP.
Here are the top five retina articles from July on Healio/OSN:
Ranibizumab, delayed photocoagulation ‘can be used in practice immediately’
Intravitreal ranibizumab with delayed laser photocoagulation effectively treated severe zone I and posterior zone II retinopathy of prematurity. Read more.
Second phase 3 trial of Zimura underway
The first patient has been dosed in a second phase 3 clinical trial of Zimura for the treatment of geographic atrophy secondary to age-related macular degeneration. Read more.
Real-world study shows long-term safety, efficacy of Iluvien in DME
Real-world long-term study outcomes showed sustained safety and efficacy of Iluvien in patients with diabetic macular edema. Read more.
Increasing dose of aflibercept may be beneficial in refractory AMD
Patients with refractory neovascular age-related macular degeneration were more likely to experience greater decreases in central foveal thickness when treated with higher doses of aflibercept. Read more.
Archway demonstrates PDS outcomes equivalent to ranibizumab
Phase 3 results of the Archway trial show patients with neovascular age-related macular degeneration treated with the Port Delivery System with ranibizumab experienced equivalent vision outcomes compared with patients treated with ranibizumab. Read more.
Collapse
Healio Coverage
Read more about
Click Here to Manage Email Alerts